2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictors
2014
Is There a Role for Postmastectomy Radiation Therapy After Complete Pathologic Response to Neoadjuvant Chemotherapy?
Housri N, Haffty B. Is There a Role for Postmastectomy Radiation Therapy After Complete Pathologic Response to Neoadjuvant Chemotherapy? Current Breast Cancer Reports 2014, 6: 38-44. DOI: 10.1007/s12609-013-0134-8.Peer-Reviewed Original ResearchPathologic complete responsePostmastectomy radiationNeoadjuvant chemotherapySmall primary tumorsAdvanced breast cancerComplete pathologic responseNode-negative diseasePostmastectomy radiation therapyInitial clinical stageTime of mastectomyMulti-institutional trialPatterns of practiceAdvanced diseasePathologic responseComplete responseClinical stagePrimary tumorBreast cancerRadiation therapyRadiation indicationsLower riskPatientsRadiation oncologistsRetrospective dataChemotherapy
2013
Non-White Women Are as Likely as White Women to Receive Hypofractionated Radiation Therapy for Breast Cancer, But Less Likely to Enroll in Hypofractionation Clinical Trials
Housri N, Khan A, Taunk N, Nelson C, Goyal S, Haffty B. Non-White Women Are as Likely as White Women to Receive Hypofractionated Radiation Therapy for Breast Cancer, But Less Likely to Enroll in Hypofractionation Clinical Trials. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s491. DOI: 10.1016/j.ijrobp.2013.06.1298.Peer-Reviewed Original Research
2009
Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973–2005)
Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG. Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973–2005). Journal Of Surgical Research 2009, 156: 340-351. PMID: 19577759, PMCID: PMC7371344, DOI: 10.1016/j.jss.2009.04.024.Peer-Reviewed Original ResearchConceptsEnd Results (SEER) databaseSurgical resectionCNS ependymomasMedian survivalResults databaseRadiation therapyMultivariate analysisIntracranial tumor locationOverall median survivalRole of surgeryFive-year survivalSignificant survival benefitLonger median survivalGrade III tumorsPrimary tumor siteLack of radiationMedian agePatient ageSurvival benefitImproved survivalIndependent predictorsAnnual incidenceMalignant ependymomaSurgical extirpationPatient survival